Table 2.
Association of TIL with prognosis (overall survival) in the whole study population
| Variable | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | ||||
| <65 | – | 0.004 | – | 0.008 |
| ≥65 | 1.620 (1.16–2.26) | 1.60 (1.13–2.27) | ||
| Gender | ||||
| Male | – | 0.55 | ||
| Female | 1.098 (0.81–1.50) | |||
| Histologic grade | ||||
| Moderate/well differentiated | – | 0.42 | ||
| Poorly differentiated | 1.16 (0.81–1.67) | |||
| Primary site | ||||
| Right | – | 0.045 | – | 0.37 |
| Left | 0.72 (0.53–0.99) | 0.85 (0.60–1.21) | ||
| T-stage | ||||
| T1–3 | – | 0.11 | ||
| T4 | 1.29 (0.95–1.75) | |||
| Lymph node status | ||||
| pN0 | – | 0.004 | – | 0.04 |
| pN+ | 1.67 (1.18–2.37) | 1.48 (1.02–2.13) | ||
| MMR status | ||||
| dMMR | – | 0.10 | ||
| pMMR | 1.89 (0.88–4.05) | |||
| Previous therapy | ||||
| De novo metastatic disease | – | 0.15 | ||
| Previous (neo)adjuvant | 0.75 (0.51–1.11) | |||
| Adjuvant chemotherapy | ||||
| Negative | – | 0.01 | – | 0.003 |
| Positive | 0.64 (0.46–0.90) | 0.58 (0.41–0.83) | ||
| Metastasectomy | ||||
| − | – | <0.001 | – | 0.02 |
| + | 0.40 (0.26–0.63) | 0.53 (0.32–0.89) | ||
| Oligometastatic status | ||||
| No | – | <0.001 | – | <0.001 |
| Yes | 0.35 (0.25–0.48) | 0.479 (0.33–0.68) | ||
| No. of metastatic organs | ||||
| 1 | – | 0.001 | – | 0.08 |
| ≥2 | 1.68 (1.24–2.28) | 1.34 (0.96–1.87) | ||
| TILs | ||||
| Low | – | 0.02 | – | 0.008 |
| High | 0.67 (0.48–0.92) | 0.624 (0.44–0.89) | ||
Note: All statistical tests were two-sided.
Abbreviations: dMMR, deficient mismatch repair; HR, hazard ratio; MMR, mismatch repair; pMMR, proficient mismatch repair; TIL, tumor-infiltrating lymphocyte.